

Barcelona, September 28th 2020

SIGNIFICANT EVENT

In accordance with Securities Markets Law approved Almirall, S.A. ("Almirall") announce the following:

The Chief Executive Officer, Mr. Peter Guenter, has communicated his decision to step down from Almirall effective 1st January 2021. The company has started searching for a person to replace Mr. Guenter to undertake his responsibilities and this will be communicated once a decision has been made.

Sincerely,

Pablo Divasson del Fraile Investor Relations Department and Corporate Spokesman investors@almirall.com



Press Release

Barcelona, España September 28th 2020

CEO Peter Guenter to leave almirall on 31/12/2020 to pursue new opportunities

. CEO Peter Guenter has decided to leave ALMIRALL on 31/12/2020

. A succession process to identify Almirall's new CEO has started

Peter Guenter, CEO, has decided to leave Almirall at the end of this year to pursue a new opportunity at a larger company. He will continue to lead Almirall for the next 3 months and will actively assist the company in anyway possible.

Jorge Gallardo Ballart, Chairman of the Board of Directors, commented: "We regret Peter's decision to pursue new opportunities. On behalf of the Board of Directors and the employees of Almirall I want to thank Peter for the impressive transformation he spearheaded at Almirall over the last years. Core Ebitda will have quadrupled, we have now one of the strongest late stage pipelines in the medical dermatology space, and we have launched successfully llumetri and Skilarence in Europe and Seysara in the US. Last but not the least, the company has been strengthened by the recruitment and development of talented employees in various parts of the organisation. We wish Peter all the best in his new endeavours and have initiated the process to identify Peter's successor.

Peter Guenter, CEO, commented: "to leave Almirall has not been an easy decision because of the great momentum that we all have created at Almirall. The company is in a much better position than it was three years ago and is poised for significant expansion with a best in class portfolio in Medical Dermatology. I want to thank the Chairman and my colleagues at the Board of Directors for the confidence and support that I have always received over the last three years.

Most importantly, I am very grateful and proud of all my colleagues at ALMIRALL who have done such a wonderful job in transforming the company into a leader in the field of Medical Dermatology. Together we have forged a strong company helping patients suffering from severe dermatological conditions". The process to identify his successor has been set in motion.

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publically traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros.

For more information, please visit almirall.com

Media contact: Tinkle Pilar Colomer <u>pcolomer@tinkle.es</u> Phone: (+34) 93 545 12 51

Investors' relations contact Almirall

Pablo Divasson del Fraile pablo.divasson@almirall.com Phone: (+34) 93 291 3087

Corporate Communications contact: Almirall Noel Ortiz <u>noel.ortiz@almirall.com</u> Phone: (+34) 93 291 30 00

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

If you wish to unsubscribe from any Almirall Corporate communication click here

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre 151, -08022-, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy. For further information, you may consult it at https://www.almirall.com/privacy-policy or contact our Data Protection Officer at the e-mail address: dpo.global@almirall.com. PRNewswire is the Agency that licenses your personal data according to their privacy policy https://gdpr.cision.com/gdpr. At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain). The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver's license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.